Evidence map›Paper›PMID 35986377›Full record

ArticleRetrovirology2022

Opposing roles of CLK SR kinases in controlling HIV-1 gene expression and latency.

Subha Dahal, Kiera Clayton, Terek Been, Raphaële Fernet-Brochu, Alonso Villasmil Ocando, Ahalya Balachandran, Mikaël Poirier, Rebecca Kaddis Maldonado, Lulzim Shkreta, Kayluz Frias Boligan and 8 more

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. CMGC Kinases in Viral Infection and Human Disease.Pathogens (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Review
  5. Viral Modulation of Host Splicing.Annual review of virology · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Subha DahalDept. of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada.
Kiera ClaytonDepartment of Pathology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
Terek BeenDept. of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada.
Raphaële Fernet-BrochuDept. of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada.
Alonso Villasmil OcandoRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Ahalya BalachandranDept. of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada.
Mikaël PoirierDept. of Microbiology & Infectious Diseases, Université de Sherbrooke, Sherbrooke, QC, Canada.
Rebecca Kaddis MaldonadoDepartment of Medicine, Penn State College of Medicine, Hershey, PA, 17033, USA.
Lulzim ShkretaDept. of Microbiology & Infectious Diseases, Université de Sherbrooke, Sherbrooke, QC, Canada.
Kayluz Frias BoliganCenter for Innovation, Canadian Blood Services, Toronto, ON, Canada.
Furkan GuvencDept. of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada.
Fariha RahmanDept. of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada.
Donald BranchCenter for Innovation, Canadian Blood Services, Toronto, ON, Canada.
Brendan BellDept. of Microbiology & Infectious Diseases, Université de Sherbrooke, Sherbrooke, QC, Canada.
Benoit ChabotDept. of Microbiology & Infectious Diseases, Université de Sherbrooke, Sherbrooke, QC, Canada.
Scott D Gray-OwenDept. of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada.
Leslie J ParentDepartment of Medicine, Penn State College of Medicine, Hershey, PA, 17033, USA.
Alan CochraneDept. of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON, M5S1A8, Canada. alan.cochrane@utoronto.ca.
Canada Research Chairs · CAUniversité de Sherbrooke · CAUniversity of Toronto · CACanadian Blood Services · CAPenn State Milton S. Hershey Medical Center · USRagon Institute of MGH, MIT and Harvard · USUniversity of Massachusetts Chan Medical School · US

Funding

Molecular Mechanisms of Retroviral Gag-RNA interactions in Virus AssemblyR01GM139392 · NIGMS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI PARENT, LESLIE J · 2020 to 2023
$1.8M
Characterization of CD8+ T cell killer activity and the mechanisms responsible for detachment from dead target cellsF32AI143480 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CLAYTON, KIERA L. · 2019 to 2020
$133k
CIHR MOP-130245CIHR PJT-165966CIHR PJT-178165NIAID NIH HHS F32 AI143480NIGMS NIH HHS R01 GM139392
6 · The paper itself

Abstract

backgroundThe generation of over 69 spliced HIV-1 mRNAs from one primary transcript by alternative RNA splicing emphasizes the central role that RNA processing plays in HIV-1 replication. Control is mediated in part through the action of host SR proteins whose activity is regulated by multiple SR kinases (CLK1-4, SRPKs).

methodsBoth shRNA depletion and small molecule inhibitors of host SR kinases were used in T cell lines and primary cells to evaluate the role of these factors in the regulation of HIV-1 gene expression. Effects on virus expression were assessed using western blotting, RT-qPCR, and immunofluorescence.

resultsThe studies demonstrate that SR kinases play distinct roles; depletion of CLK1 enhanced HIV-1 gene expression, reduction of CLK2 or SRPK1 suppressed it, whereas CLK3 depletion had a modest impact. The opposing effects of CLK1 vs. CLK2 depletion were due to action at distinct steps; reduction of CLK1 increased HIV-1 promoter activity while depletion of CLK2 affected steps after transcript initiation. Reduced CLK1 expression also enhanced the response to several latency reversing agents, in part, by increasing the frequency of responding cells, consistent with a role in regulating provirus latency. To determine whether small molecule modulation of SR kinase function could be used to control HIV-1 replication, we screened a GSK library of protein kinase inhibitors (PKIS) and identified several pyrazolo[1,5-b] pyridazine derivatives that suppress HIV-1 gene expression/replication with an EC

conclusionsThese findings demonstrate the unique roles played by individual SR kinases in regulating HIV-1 gene expression, validating the targeting of these functions to either enhance latency reversal, essential for "Kick-and-Kill" strategies, or to silence HIV protein expression for "Block-and-Lock" strategies.

Indexed as

HIV-1Alternative SplicingGene ExpressionProtein Kinase InhibitorsRNA, ViralVirus LatencyProtein Kinase InhibitorsRNA, ViralHIV-1LatencyRNA processingSR kinases

Identifiers

PMID35986377
PMCPMC9389714
OpenAlexW4292299706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.